Novavax Inc and its partner Serum Institute of India have applied to the World Health Organization for an emergency use listing of Novavax’s COVID-19 vaccine, potentially clearing the way for the shot to ship to many poorer countries, the company said on Thursday.Novavax has been prioritizing regulatory submissions to low- and middle-income countries after falling behind in the race for authorization in the United States and Europe, which have already vaccinated most of their residents.
Novavax starts early trials for combined flu and COVID-19 vaccine A WHO listing would allow Novavax to ship to multiple developing nations that rely on WHO guidance for their regulatory decisions.It would also allow Novavax to begin distributing shots.